M
Madeleine W. Cunningham
Researcher at University of Oklahoma Health Sciences Center
Publications - 145
Citations - 11788
Madeleine W. Cunningham is an academic researcher from University of Oklahoma Health Sciences Center. The author has contributed to research in topics: Epitope & Autoantibody. The author has an hindex of 53, co-authored 141 publications receiving 10723 citations. Previous affiliations of Madeleine W. Cunningham include University of Oklahoma.
Papers
More filters
Journal ArticleDOI
Pathogenesis of Group A Streptococcal Infections
TL;DR: Group A streptococci are model extracellular gram-positive pathogens responsible for pharyngitis, impetigo, rheumatic fever, and acute glomerulonephritis, and an emerging theme is the dichotomy between skin and throat strains in their epidemiology and genetic makeup.
Journal ArticleDOI
Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation.
TL;DR: A murine monoclonal anti-platelet antibody is developed and characterized that binds to activated platelets, but not to unstimulated platelets and inhibits fibrinogen-mediated platelet aggregation.
Journal ArticleDOI
Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea.
TL;DR: Chorea monoclonal antibodies showed specificity for mammalian lysoganglioside and N-acetyl-β-D-glucosamine (GlcNAc), the dominant epitope of the group A streptococcal (GAS) carbohydrate, which will lead to a better understanding of other antibody-mediated neurological disorders.
Journal ArticleDOI
Acute rheumatic fever and rheumatic heart disease
Jonathan R. Carapetis,Jonathan R. Carapetis,Andrea Beaton,Madeleine W. Cunningham,Luiza Guilherme,Luiza Guilherme,Ganesan Karthikeyan,Bongani M. Mayosi,Craig Sable,Andrew C Steer,N. Wilson,Rosemary Wyber,Liesl Zühlke +12 more
TL;DR: Progress in developing group A streptococcal vaccines and an increased focus on the lived experience of those with RHD and the need to improve quality of life give cause for optimism that progress will be made against this neglected disease.
Journal ArticleDOI
Usefulness of Immunosuppression for Giant Cell Myocarditis
Leslie T. Cooper,Joshua M. Hare,Henry D. Tazelaar,William D. Edwards,Randall C. Starling,Mario C. Deng,Santosh G. Menon,G.Martin Mullen,Brian E. Jaski,Kent R. Bailey,Madeleine W. Cunningham,G. William Dec +11 more
TL;DR: This prospective study of immunosuppression for GCM confirms retrospective case reports that such therapy improves long-term survival and can be associated with fatal GCM recurrence, and demonstrates for the first time that there is a risk of recurrent, sometimes fatal, GCM after cessation of immunsuppression.